In Greece, the reimbursement of rare disease treatments is managed by the national health authority, the National Organization for Health Care Services Provision (EOPYY). The reimbursement process for rare disease treatments in Greece is governed by a set of guidelines and regulations that aim to ensure fair and equitable access to treatments for patients with rare diseases.
The process for reimbursement of rare disease treatments in Greece begins with an application from the pharmaceutical company to EOPYY. The application includes information on the clinical and cost-effectiveness of the treatment, as well as data on the prevalence of the rare disease in Greece.
Once the application is received, it is reviewed by a committee of medical experts and health economists who evaluate the clinical and cost-effectiveness of the treatment. The committee also considers the impact of the treatment on the national health budget and the availability of alternative treatments.
If the treatment is approved for reimbursement, it is added to the Greek National Formulary, which is the list of reimbursed drugs and medical products available to patients. The reimbursement amount is determined by the Greek Ministry of Health, based on the price of the treatment in other European countries and the available budget for healthcare.
It is important to note that the reimbursement process for rare disease treatments in Greece can be complex and challenging, as the patient population is often small and the cost of treatment may be high. However, EOPYY is committed to ensuring that patients with rare diseases have access to the treatments they need, and they work closely with pharmaceutical companies and patient advocacy groups to facilitate the reimbursement process.